Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

33.42USD
2 Dec 2016
Change (% chg)

$-0.07 (-0.21%)
Prev Close
$33.49
Open
$34.15
Day's High
$34.18
Day's Low
$33.11
Volume
612,879
Avg. Vol
1,151,953
52-wk High
$42.15
52-wk Low
$27.50

Latest Key Developments (Source: Significant Developments)

The Medicines Co reports Q2 earnings per share of $2.51 from continuing operations
Wednesday, 27 Jul 2016 07:00am EDT 

The Medicines Company Reports Second : "completed divestiture of non-core cardiovascular assets" . Quarter 2016 business and financial results . Q2 earnings per share $2.51 from continuing operations . Q2 revenue $54.7 million versus $74.5 million . Q2 adjusted loss per share $0.62 from continuing operations . Q2 revenue view $41.9 million -- Thomson Reuters I/B/E/S .Q2 earnings per share view $-1.16 -- Thomson Reuters I/B/E/S.  Full Article

Medicines Co gives Federal circuit rules for Medicines Co in Angiomax litigation
Tuesday, 12 Jul 2016 07:02am EDT 

Medicines Co [MDCO.O] : Federal circuit rules for medicines company in angiomax patent litigation . Federal circuit said company's orange book patents covering Angiomax(reg) that expire in 2028 were not invalid under "on sale" bar .Federal circuit also remanded remainder of issues on appeal and cross-appeal to original federal circuit panel.  Full Article

The Medicines Company prices $350 million of convertible notes
Monday, 6 Jun 2016 10:13pm EDT 

Medicines Co : Prices $350 million of convertible notes . Says priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023 . Says notes will bear interest at a rate of 2.75% per year, payable semi-annually . Expects to use portion of net proceeds of offering to repurchase approximately $220 million of its 1.375% convertible notes due 2017 . Conversion rate for notes will initially be 20.4198 shares of common stock per $1,000 principal amount . Estimates that net proceeds from offering will be approximately $339.7 million .Expects to use approximately $29.5 million of net proceeds from offering to pay cost of capped call transactions.  Full Article

Medicines Co intends to offer $350 mln of convertible notes
Monday, 6 Jun 2016 06:57am EDT 

Medicines Co : The medicines company announces intention to offer $350 million of convertible notes . Proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023 . Expects to use a portion of net proceeds of offering to repurchase approximately $220 million of its 1.375% convertible notes due 2017 .Expects to grant to initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of notes.  Full Article

Medicines expects to incur about $18 mln-$22 mln of pre-tax charges
Friday, 13 May 2016 04:57pm EDT 

Medicines Co : Estimates it will incur approximately $18 million to $22 million of pre-tax charges primarily during q2 of 2016 - sec filing .Pre-Tax charges in connection with company's entrance into purchase and sale agreement to divest certain cardiovascular products.  Full Article

The Medicines Co to divest non-core cardiovascular assets
Monday, 9 May 2016 07:22am EDT 

The Medicines Company : Total consideration of up to $792 million . Deal will result in anticipated reduction in annual SG&A and related research and development expenses of between $65 million and $80 million . To sell Cleviprex(Clevidipine), Kengreal(Cangrelor) and company's rights to Argatroban for injection to Chiesi USA, Inc and its parent company, Chiesi Farmaceutici S.p.a .Core cardiovascular assets to Chiesi Farmaceutici S.p.a.  Full Article

Medicines Co Q1 loss per share $1.31 from continuing operations
Monday, 9 May 2016 07:14am EDT 

The Medicines Company : Quarter 2016 business and financial results . Q1 loss per share $1.31 from continuing operations . Q1 revenue $50.3 million versus I/B/E/S view $50.2 million . Q1 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S .Q1 adjusted loss per share $1.03 from continuing operations.  Full Article

Medicines Co agrees to divest its Hemostasis Portfolio to Mallinckrodt plc
Friday, 18 Dec 2015 08:45am EST 

Medicines Co:Entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three hemostasis products.Medicines Company will receive an initial payment of approximately $175 million.Leerink Partners LLC is acting as financial advisor, and WilmerHale is acting as legal advisor, to The Medicines Company.  Full Article

Glenn Sblendorio To Retire as President and Chief Financial Officer from The Medicines Company
Wednesday, 9 Dec 2015 05:03pm EST 

The Medicines Company:Sasy Glenn Sblendorio, President and Chief Financial Officer, will retire from company effective March 31, 2016.As of January 1, 2016, Mr. Sblendorio will be relinquishing his seat on the Board of Directors and his operational responsibilities will be assumed by others within the company.William O'Connor, Senior Vice President & Chief Accounting Officer, who has been with The Medicines Company since 2006, will succeed Sblendorio as Chief Financial Officer.Sblendorio will continue as a strategic advisor to Clive Meanwell, MD, PhD, Chief Executive Officer of the company, until the end of March.  Full Article

Medicines Co and SymBio Pharmaceuticals establish strategic partnership for IONSYS (fentanyl iontophoretic transdermal system) in Japan
Tuesday, 6 Oct 2015 05:12pm EDT 

Medicines Co:Says the company and SymBio Pharmaceuticals Ltd announced the establishment of a strategic partnership for IONSYS (fentanyl iontophoretic transdermal system) in Japan.Partnership includes an agreement granting SymBio an exclusive license in Japan to develop and commercialize IONSYS.Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include a $10 million upfront payment and certain regulatory and commercial milestones.  Full Article

BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries

* Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to Hepatitis C treatment in developing countries